Company intelligence / Profile preview
PinotBio
Suwon, South Koreapinotbio.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
Completed Phase 1a of NTX-301 for blood cancer in the US in May 2024 and started Phase 1b/2a in August 2024. Also completed Phase 1a clinical trial of NTX-301 for solid cancer in the US in December 2019.
- Therapeutic areas
- OphthalmologyHematologyOncology
- Modalities
- Antibody-drug conjugates (ADCs)small molecules
- Industry
- Biotech
02
Drug pipeline
8 assets7 more assets in the full pipeline.
Request access →03
Partnerships
CelltrionConjugatebio Inc.
Beyond the preview
Go deeper on PinotBio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PinotBio.